Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial

Journal of Diabetes and Metabolic Disorders

Volumn 14, Issue 1, 2015, Pages

  Bashier, Alaaeldin M K ^a   Hussain, Azza Abdulaziz Khalifa Bin ^a   Abdelgadir, Elamin Ibrahim Elamin ^a   Eltinay, Ahmed Tarig ^a   Thadani, Puja ^a   Abdalla, Mohamed Elhassan ^b   Abusnana, Salah ^c   AlAwadi, Fatheya F ^a  

^a DUBAI HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF SHARJAH   (United Arab Emirates)

^c RCDR Centre   (United Arab Emirates)

Author keywords

Arab population; Blood pressure; HbA1c; Liraglutide; Type2 diabetes mellitus; Weight

Indexed keywords

ANTIHYPERTENSIVE AGENT; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LIRAGLUTIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARAB; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RASH; TREATMENT DURATION; URTICARIA; WEIGHT REDUCTION;

EID: 84939209734     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/s40200-015-0178-6     Document Type: Article

References (24)

1. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal aα-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283:109-15.
2. Dunning BE, Gerich JE. The role of aα-cell dys-regulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev. 2007;28:253-83.
3. Matsumoto S, Yamazaki M, Kadono M, Iwase H, Kobayashi K, Okada H, et al. Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes. J Clin Biochem Nutr. 2013;53(1):68-72.
4. Seino Y, Rasmussen MF, Katayama Y, Kaku K. The human GLP-1 analogue liraglutide given once daily provides excellent metabolic control in Japanese patients either as monotherapy or in combination with SU during 52 weeks of treatment. Diabetologia. 2009;52 Suppl 1:S292.
5. Ramachandran A, Ma RCW, Snehalatha C. Diabetes in Asia. Lancet. 2010;375:408-18.
6. Seino Y. Relevance of incretins in the treatment of Asian patients with Type2 diabetes. Diab Res Clin Pract. 2008;79:S4.
7. Seino Y, Rasmussen MF, Katayama Y, Kaku K. Liraglutide is statistically superior to glibenclamide at controlling glycemia and weight, with low hypoglycemic risk, and improves beta-cell function in Japanese subjects with T2D. [Abstract 536-P], Abstracts of the American Diabetes Association (ADA) 69th Scientific Session. 2009.
8. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose dependent improvement in glycaemia with once-daily liraglutide without hypoglycemia or weight gain: a double blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diab Res Clin Pract. 2008;81:161-8.
9. Khalil AB, Beshyah SA, Benbarka MM, Jeanette DB, Roos B. The effect of sitagliptin therapy in suboptimally controlled metformin-treated type 2 diabetes patients: a Middle Eastern experience. Int J Diabetes Metab. 2010;18:55-8.
10. ADA. Standards of care in diabetes. Diabetes Care. 2014;37(Supplement 1):14-80.
11. Sethi BK, Viswanathan V, Kumar A, Chatterjee S, Chandalia HB. Liraglutide in clinical practice: insights from LEAD programme. JAPI. 2010;58:18-22.
12. Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type2 diabetes. Curr Med Res Opin. 2010;26(5):1013-22.
13. Yuya F, Norikazu M, Kana I, Susumu K, Hitoshi N, Ayumu H, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol. 2012;11:107.
14. Melva L, Madoka T, Takeuchi M, Nafrialdi, Rianto S. Incretin-based therapies for type 2 diabetes mellitus in Asian patients: analysis of clinical trials. Med J Indones. 2010;19:205-12.
15. Kendall DM, Riddle MC, Rosenstock J, Zuang D, Kim DD, Fineman MS, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diab Care. 2005;28:1083-91.
16. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease, pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968-76.
17. Backman L, Freyschuss U, Hallberg D, Melcher A. Reversibility of cardiovascular changes in extreme obesity. Effects of weight reduction through jejunoileostomy. Acta Med Scand. 1979;205:367-73.
18. Backman L, Freyschuss U, Hallberg D, Melcher A. Cardiovascular function in extreme obesity. Acta Med Scand. 1973;193:437-46.
19. Sanjoy P, Kerenaftali K, David M, Jennie B. The association of the treatment with glucagon-like peptide-1 receptor exenatide or insulin with cardiovascular outcomes in patients with type2 diabetes: a retrospective study. Cardiovasc Diabetol. 2015;14:10. doi: 10.1186/s12933-015-0178-3.
20. Plutzky J, Garber AJ, Falahati A, Toft AD, Poulter NR. The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials. Eur Heart J. 2009;30 Suppl 1:917.
21. Kana I, Norikazu M, Yuya F, Shiro F, Hirofumi N, Masaya Y, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetol Metab Syndr. 2014;6:95.
22. Fonseca V, Falahati A, Zychma M, Madsbad S, Plutzky J. A meta-analysis of six clinical trials demonstrates that the once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure. Diabetologia. 2009;52 Suppl 1:S299.
23. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737-49.
24. Giorda CB, Nada E, Tartaglino B. Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. Endocr. 2014;46(3):406-19.